Reuters logo
BRIEF-Redhill Biopharma announces expected timeline for DSMB meeting
2017年7月12日 / 中午12点21分 / 4 个月前

BRIEF-Redhill Biopharma announces expected timeline for DSMB meeting

July 12 (Reuters) - Redhill Biopharma Ltd:

* Redhill Biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb-104 phase iii study for Crohn’s disease

* Redhill Biopharma - ‍second independent dsmb meeting of RHB-104 phase III study for Crohn’s disease is planned to be held in late July 2017​

* Says ‍redhill expects to announce recommendation of DSMB meeting by early August 2017​

* Redhill Biopharma Ltd - ‍to date, approximately 300 patients of planned total of 410 patients have been enrolled in ongoing phase III map us study​

* Redhill Biopharma - ‍assuming study is not stopped following DSMB meeting, completion of recruitment for map U.S. Study expected by beginning of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below